Today: 10 June 2026
XRP price slides 7% toward $2 as ETF outflows hit and jobs data looms
8 January 2026
1 min read

XRP price slides 7% toward $2 as ETF outflows hit and jobs data looms

New York, January 8, 2026, 06:26 ET — Premarket

XRP fell about 7% to around $2.09 on Thursday, pulling back after a sharp early-year run for the Ripple-linked token. Bitcoin was down about 2.2% at $90,059 and ether slipped about 3.2% to $3,119.

The slide came as U.S. spot XRP exchange-traded funds (ETFs) logged their first net outflow day since launch, with about $40.8 million leaving on Wednesday, Cointelegraph reported, citing SoSoValue data. A spot ETF holds the underlying asset, rather than tracking it through futures contracts.

That matters now because ETF flow has been the market’s cleanest signal of marginal demand for XRP in recent weeks. Earlier this week, about $46 million flowed into U.S. spot XRP ETFs on Monday, and the products had not recorded a net outflow since their mid-November debut, Barron’s reported, citing Coinglass.

Macro nerves added to the drag. U.S. stock index futures edged lower ahead of Friday’s nonfarm payrolls report, Reuters reported, as investors positioned for the government’s monthly snapshot of hiring and wage growth.

Crypto traders also ran into a leverage hangover after the early-January bounce. “Bitcoin drifted lower toward the low-$92,000s,” Iliya Kalchev, a Nexo Dispatch analyst, said in comments shared with The Defiant, as markets weighed geopolitics and incoming U.S. data; Coinglass data cited in the report showed roughly $278 million in leveraged positions were liquidated over 24 hours, including about $11 million in XRP. Liquidations are forced closures when traders cannot meet margin requirements. The Defiant

On the chart, traders have been pointing to the $2.28 area as a trouble spot after repeated failures there, CoinDesk reported, a level some short-term players treated as near-term resistance. The round-number $2 mark is the next line many will watch if the selloff deepens.

The broader backdrop is still being shaped by the rush of mainstream firms into crypto wrappers. Morgan Stanley has filed with the U.S. SEC to launch bitcoin and solana ETFs, and “a bank entering the crypto ETF market adds legitimacy,” Morningstar ETF analyst Bryan Armour said in the Reuters report. Reuters

But ETF flows can turn quickly, and XRP has a habit of amplifying risk-on and risk-off swings. If the jobs data surprise on the upside and push rates higher, traders say the pressure could spread from bitcoin into smaller tokens, with outflows compounding the move.

Stock Market Today

  • 3 High ROE Stocks With Solid Balance Sheets Highlighted for Investors
    June 10, 2026, 9:01 AM EDT. Investors seeking stability amid inflation and geopolitical tensions may focus on companies with high return on equity (ROE) and robust balance sheets. Regis Resources (ASX:RRL) stands out with a 25.7% ROE, strong revenue from Australian gold projects, and forecasts of earnings growth above 20%. However, it faces risks from gold price fluctuations and project approvals. Aristocrat Leisure (ASX:ALL) features as a global gaming technology leader with substantial revenue streams and solid financial fundamentals. These stocks provide potential resilience against margin pressure and volatile input costs, offering a grounded starting point for quality-focused investment research.

Latest articles

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

10 June 2026
BlackBerry shares dropped 4.84% to $8.84 Tuesday and slid further to $8.42 premarket Wednesday, erasing part of a 49% rally as investors question whether QNX and Secure Communications growth can justify recent gains ahead of Q1 fiscal 2027 earnings on June 25; the stock is now down 14.5% from last week’s close.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

10 June 2026
Nuvalent soared 39.28% to $123.25 after GSK agreed to buy the company for $124 per share in cash, leaving a narrow 0.6% spread as investors shift focus to the $10.6 billion merger’s tender-offer timing, antitrust review, and FDA decision dates for two lung-cancer drugs in September and November 2026.
EV Stocks Mixed in Premarket: Rivian Rises Despite Recall as Tesla, Lucid Slip
Previous Story

EV Stocks Mixed in Premarket: Rivian Rises Despite Recall as Tesla, Lucid Slip

Broadcom stock (AVGO) slides as Nvidia’s China chip payment demand ripples through AI semiconductors
Next Story

Broadcom stock (AVGO) slides as Nvidia’s China chip payment demand ripples through AI semiconductors

Go toTop